ERBB2 and ovarian neoplasm: In this study, we demonstrate for the first time the capacity of ACE from HER-2/neu-overexpressing primary ovarian tumour cells to induce in vitro autologous CTL from MEAMNC with the ability to exert in vivo antitumour effects against HER-2/neu+ human tumour cell lines.